Next-generation therapeutics to address antimicrobial resistance

Antimicrobial resistance (AMR) poses a threat to global health and there is a growing need to develop new therapeutics that overcome this concern. David Powell, ELRIG Drug Discovery plenary keynote speaker and Chief Scientific Officer, LifeArc, discusses the current state AMR, the approaches needed to ensure effective therapeutic development, and the role of both science and economics in bringing new antimicrobial therapeutics to market. Learn how LifeArc is helping to address the threat of AMR through a new partnership with Innovate UK and Medicines Discovery Catapult (MDC), that aims to accelerate early-stage antimicrobial drug and diagnostic discovery.

Interview filmed at ELRIG Drug Discovery 2023.